Company: SXTPW
Filing Date: 2025-09-05
Form Type: 424B5
Source: 0001213900-25-085050
Chunk: 54

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-09-05
Form: 424B5
Chunk 54
---
 babesiosis 
 and that according to Krause et al (AJTMH 2003;6:431-436) fact that about 80% of cases are symptomatic (thus 476,000*10%*80% = 38,000   
 cases of babesiosis per year).                                                                                                          |

| 11 | Bloch et al Open Forum Infect Dis 2022;9(11):ofac597. |

| 12 | According to IDSA guidelines. |

| 13 | See Krause et al Clin Infect Dis 2024; doi:10.1093/cid/ciae238                                                  
 and https://ysph.yale.edu/news-article/antimalarial-drug-is-effective-against-tick-borne-infection-babesiosis/. |

| 14 | Marx et. al., MMWR 2021;70:612-616. |

| 15 | https://www.cdc.gov/fungal/diseases/candidiasis/invasive/statistics.html.; 
 https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html.            |

| 16 | Dow and Smith New Microb New Infect 2022;45:100964. |

<div align='center'>3</div>

| ● | Prevention of fungal pneumonias. There are up to ~ 91-92,000 new patient cases  each year in the United States for which antifungal prophylaxis is recommended, including acute lymphoblastic leukemia (up to 6,540 cases) and large B-cell lymphoma (up to 18,000 cases) patients receiving CAR-T therapy, solid organ transplant patients (up to 42,887 cases), allogeneic (~ 9,000 cases) and autologous (~ 15,000 cases) hematopoietic stem cell transplant patients.17 Despite the availability and use of antifungal prophylaxis, the risk of some patient groups contracting fungal pneumonia exceeds the risk of contracting malaria during travel to West Africa.18 Since it has broad spectrum antifungal effects in cell culture, and activity against Pneumocystis in animal models, Tafenoquine has the potential to be added to existing standard of care regimens for the prevention of fungal pneumonias.19 |

Viral Diseases Celgosivir, a potential clinical candidate of 60P’s, has activity in a number of animal models of important viral diseases such as Dengue and R